Tag Archives: investor

Hot Investor Mandate 1: Newly Founded Family Office Actively Seeking Early-Stage Life Science Investments, from Pre-Clinical Stage Assets to Medical Devices

15 Mar

A newly formed Delaware family office investment vehicle representing East Coast-based family interests is looking to invest in ground-breaking life science and medical device technologies. While the firm is very flexible in terms of investment size, they are generally looking to invest a minimum of $0.5 million per round. The firm is open to Investing in companies located throughout North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Device and Diagnostics Sectors that address underserved medical needs, or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis and are especially interested in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell- based therapeutics.

The firm is less interested in small molecules and generally will not consider biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease- modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets. The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency.

For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , ,

Hot Investor Mandate 2: Chinese Government Partnered VC Firm Invests in Therapeutics and Clinical Testing Companies, with Focus on China Angle

15 Mar

A venture capital firm partnered with the Chinese Government was founded in 2016, and focuses on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. With the Chinese Government partnership, the firm seeks to bring good projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also willing to look at medical devices to a small degree but is not very familiar with those technologies. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , , ,

Hot Investor Mandate 3: Investment Arm of Major China Genomics Company Looks for Complementary Early-Stage Genomics & Big Data/AI Technologies

15 Mar

A branch of a subsidiary of a major genomics sequencing company in China is actively seeking technologies from the US, Canada, and China that will complement what they currently have. In addition to direct investments, the firm often functions as a strategic partner that can help provide a technology platform for a startup or even integrate the new technology into their system. The firm also provides access to their large marketing team once the product is developed to help the startup during their commercialization phase. The firm is currently interested in early stage companies: usually at seed to series A and is rather flexible as to the financing terms. Additionally, the firm is willing to work through either partnerships or direct investments.

The firm is actively seeking new genomics technologies. Currently, the firm is interested in any technology within diagnostics, digital health, and medtech that has a focus on genomics. Within the diagnostics and medtech sectors, the firm is particularly interested in sequencing technologies currently, but is willing to see all early stage genomics-based technologies within these sectors. For digital health, the firm is interested in companies involved in big data and AI that already have algorithms that can utilize the large pool of genomics data that the firm currently has access to.

When investing, the firm likes to take an active role in the company and prefers taking board seats but does not require a board seat. Otherwise, the firm prefers to work with companies that the firm can work with and help develop into either a potential integration or a productive partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , , , ,

RESI Is Now Offering Investor Spotlight Package

22 Feb

By Natasha Eldridge, Director of RESI Conference Series, LSN

natasha-wp-newThe Redefining Early Stage Investments Conference (RESI) is now offering an Investor Spotlight Package, which for the first time allows investor firms to be featured and stand out from more than 300+ investors attending the 2018 RESI Toronto conference.

Investor Spotlight Package includes the following:

  • A Dedicated, Branded Partnering Table in the partnering forum. This is your table and a great opportunity to have an established highly visible spot in the partnering room where companies can meet you. The table will be branded by your firm’s logo and name.
  • Featured Investor Profile on the RESI website, in the hard copy and digital version of the RESI Conference Program Guide, and in the RESI Partnering System – making your investment mandate visible to RESI attendees.
  • Special mailings of your firm’s profile to all RESI Companies that are a fit for your firm’s mandate.

To qualify you must be:

  • Investment staff involved directly in an early-stage life science or healthcare venture capital or private equity fund.
  • Investment staff at a family office or private wealth fund that invests in life sciences.
  • External innovation, early-stage partnering or in-licensing staff from major corporations in the life science and healthcare industry.
  • Active life science angels or executive staff at angel organizations that invest in early-stage life science companies.
  • Investment staff and executives at nonprofit organizations, venture philanthropy/impact investment firms or patient groups that provide funding to startup companies.
  • Senior management or investment staff from a pension, endowment, foundation or employee benefit plan currently invested in life sciences.

For more information, please contact us

at 617-600-0668 or resi@lifesciencenation.com

22

Tags: , ,

An Investor Database That Works

8 Feb

By Lucy Parkinson, Director of Research, LSN

LSN created the LSN Investor Platform, which is the only early stage life science investor platform that goes across the silos of drugs, devices, diagnostics and healthcare IT. Over 600 clients have used this service, raising millions of dollars from investors located all around the globe. We’ve recently updated our video to reflect the latest generation of the cloud-based investor and strategic partnering database – take a look below!

Tags: , ,

Over 400 Qualified Life Science Investors Registered For Redefining Early Stage Investments (RESI) Conference at JP Morgan, Jan 9th at Marine Memorial Hotel, Union Square

28 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

RESI is different, in that, the LSN research team actually qualifies all the investors that attend the RESI conference. The LSN researchers, through one-on-one phone conversations, validate that all the investors have current or future mandates to invest in early stage technology assets across the domains of drugs, devices, diagnostics or healthcare IT. Fundraising CEOs and scientist entrepreneur’s don’t have to guess who they are meeting with on the other side of the table. As a matter of fact, we kindly ask the I-banks, broker dealers and debt providers to sign up as service providers so the fundraisers know who’s who in the whirlwind of meetings taking place at RESI. This will be our fourth RESI @ JPM and we expect to close down registrations due to the capacity constraint on the Marine Memorial Hotel in Union Sq. The good news is we are still accepting registrations “click here to register”.

RESI @ JPM will be the most compelling event LSN has held because the investor to fundraiser ratio will be 1-to-1, as amazing as that sounds. If you are a fundraising executive please take advantage of this opportunity to meet investors that are a fit for your stage of development and product set. RESI Partnering is now up and running with half of the meetings now booked. There is still time to dramatically impact the number of investors on your radar screen. Raising money is a numbers game, and RESI was created to help identify investors that are a fit, create a dialogue, and foster relationships that help you move towards allocations. Please scroll down and see the investors currently signed up for RESI at JPM.

Tags: , ,

Orphan Drug Investors Discuss the Current Rare Disease Environment during RESI@JPM

21 Dec

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

A large number of early stage biotechs are pursuing orphan disease indications.  This trend is driven by the large number of rare diseases with either no current treatment options or severely inadequate therapies as well as the unique regulatory/development advantages available for these therapeutics. However, orphan drugs also face some unique challenges, such as clinical trial recruitment, pricing, and small market sizes. Recent developments in the space should make for an interesting year to come with the new FDA head, Dr. Scott Gottlieb, planning to eliminate the backlog of orphan drug designation requests and the halving of the orphan drug tax credit.

In the highly anticipated RESI @ JPM conference on January 9, 2018, a varied group of investors active in the orphan/rare disease space will discuss the financing and business development environment for startups working on developing drugs for orphan indications.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital panelists include:

Tags: , , , ,

← Older Entries
Newer Entries →